APEX Tissue
Targeted Genomic Profiling for Non-Small Cell Lung Cancer, Colorectal Cancer & Breast Cancer
APEX Tissue is a 50-gene, targeted Next-Generation Sequencing (NGS) hotspot panel, which is specially curated for the detection of sensitizing and resistance genetic alterations to guide personalized treatment selection in patients with solid tumours.
Cancer Treatment Selection
Actionable, Personalized, EXpress (APEX)
Benefits
Fast Results
Short turnaround time of
4 working days* to allow quicker treatment initiation
Affordable
Competitively priced for greater affordability and accessibility
Targeted
Targeted hotspot sequencing of 50 genes specially curated based on clinical actionability
DNA & RNA
Profiling both DNA and RNA for reliable detection of genetic alterations
Validated
APEX Tissue has been clinically validated
More Information
Profiling various types of genetic alterations, such as SNVs, InDels, amplifications, and fusions, in a single test
Guidelines
Including treatment recommendations based on FDA approvals, NCCN and ESMO guidelines
Concise Report
Easy-to-read report with tier classification of variants for quick decision making
Short turnaround time of
4 working days* to allow quicker treatment initiation
Competitively priced for greater affordability and accessibility
Targeted hotspot sequencing of 50 genes specially curated based on clinical actionability
Profiling both DNA and RNA for reliable detection of genetic alterations
APEX Tissue has been clinically validated
Profiling various types of genetic alterations, such as SNVs, InDels, amplifications, and fusions, in a single test
Including treatment recommendations based on FDA approvals, NCCN and ESMO guidelines
Easy-to-read report with tier classification of variants for quick decision making
*Counting from the day the specimen is received at our laboratory in Singapore. SNVs: single nucleotide variants; InDels: insertions and deletions.
Patient Profiles Suitable for APEX Tissue
Newly diagnosed, treatment-naïve patients with advanced NSCLC for 1L treatment selection.
Relapsed patients who progressed on 1L/2L EGFR, ALK or ROS1 TKI.
Newly diagnosed, treatment-naïve patients with metastic CRC, in which testing for KRAS/NRAS/BRAF status is intended.
HR+/HER2- BC patients who progressed on CDK4/6 inhibitor + AI, in which testing for resistance mutations is intended.
Note: Not suitable for patients who have failed multiple treatments and exhausted most treatment options. A larger panel may be warranted in these patients
Gene List (50 genes)
Guidelines Recommended Genetic Biomarkers Testing for Solid Tumours 1-10
Updated as of 29 March 2022
Ordering Process for Physicians
Step 1
Request a kit online or contact our local representative
Step 2
Obtain informed consent from patient
Step 3
Request tissue slides and histopathology report from pathology laboratory
Step 4
Place all forms and slides in the box provided
Step 5
Contact our local representative to arrange for pickup and courier to Singapore laboratory
Step 6
Receive clinical report after 4 working days from kit receipt at the laboratory
1 National Comprehensive Cancer Network. Non–Small Cell Lung Cancer (Version 3.2022). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed on 18 March 2022.
2 National Comprehensive Cancer Network. Breast Cancer (Version 2.2022). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed on 18 March 2022.
3 National Comprehensive Cancer Network. Colon Cancer (Version 1.2022). https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed on 18 March 2022.
4 National Comprehensive Cancer Network. Rectal Cancer (Version 1.2022). https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed on 18 March 2022.
5 National Comprehensive Cancer Network. Melanoma: Cutaneous (Version 2.2022). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed on 18 March 2022.
6 National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) (Version 1.2022). https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf. Accessed on 18 March 2022.
7 National Comprehensive Cancer Network. Bladder Cancer (Version 1.2022). https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed on 18 March 2022.
8 National Comprehensive Cancer Network. Thyroid Carcinoma (Version 3.2021). https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed on 18 March 2022.
9 National Comprehensive Cancer Network. Hepatobiliary Cancers (Version 5.2021). https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed on 8 March 2022
10 Mosele F et al. Recommendations for the Use of Next-Generation Sequencing (NGS) for Patients with Metastatic Cancers: A Report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020 Nov;31(11):1491-1505